Drug Type Recombinant protein |
Synonyms- |
Target |
Mechanism DDR1 antagonists(Discoidin domain receptor 1 antagonists), ERK inhibitors(ERK subfamily inhibitors), PYK2 inhibitors(Focal adhesion kinase 2 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Preclinical | CN | 11 Dec 2023 |